Key result
Severe dynamic LVOT obstruction predicts ~87% higher risk of adverse clinical outcomes in HCM.
Why the study?
Although LVOT obstruction influences functional capacity and clinical outcomes in HCM, the clinical relevance of varying obstruction severity remains debated.
Does severe LVOT obstruction (≥80 mmHg) predict worse exercise performance and long-term prognosis in patients with hypertrophic cardiomyopathy?
Cohort (n=388)
Does severe LVOT obstruction (≥80 mmHg) predict worse exercise performance and long-term prognosis in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Severe dynamic LVOT obstruction (≥80 mmHg) identifies a high-risk subgroup of HCM patients with impaired exercise capacity and worse long-term prognosis, highlighting the value of TTE-CPET for risk stratification.
Background Hypertrophic cardiomyopathy (HCM) is a complex disease in which left ventricular outflow tract (LVOT) obstruction influences both functional capacity and clinical outcomes. However, the clinical relevance of varying obstruction severity remains debated. Objectives To evaluate the relationship between LVOT gradient severity and both exercise performance and long–term prognosis in HCM using combined cardiopulmonary exercise testing and stress echocardiography (TTE–CPET). Methods We retrospectively analysed 388 HCM patients undergoing TTE–CPET, stratified into four groups based on peak LVOT gradient: ‹30 mmHg, 30–49 mmHg, 50–79 mmHg, and ≥80 mmHg. Clinical, echocardiographic, and CPET data were compared. The primary outcome was a composite of NYHA class worsening, heart failure hospitalization, new–onset atrial fibrillation, or progression to end–stage HCM, assessed over a median follow–up of 7.4 years. Results Only patients with severe obstruction (≥80 mmHg, n=82) showed significantly lower peak VO₂ (15.9 vs. 19.7 ml/kg/min, p=0.003, Figure 1), higher pulmonary pressures, more advanced diastolic dysfunction, and greater symptom burden. They also had a higher incidence of adverse events (50.0% vs. 31.6%, p=0.011) and worse event–free survival (log–rank p=0.011). A peak gradient ≥80 mmHg independently predicted adverse outcomes (HR: 1.87; p=0.009), even after adjustment. Patients with intermediate gradients (30–79 mmHg) had generally preserved outcomes, though some exhibited early structural or functional changes Conclusions Severe dynamic LVOT obstruction identifies a high–risk HCM subgroup with impaired exercise capacity and poor prognosis. Intermediate gradients may still warrant close monitoring. TTE–CPET offers critical insight for risk stratification and early intervention.
No takes yet. Share an insight, caveat, or question.
Mistrulli et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (n=388). Severe dynamic LVOT obstruction (peak gradient ≥80 mmHg) vs. Non-severe LVOT obstruction (<80 mmHg) was evaluated on Composite of NYHA class worsening, heart failure hospitalization, new-onset atrial fibrillation, or progression to end-stage HCM (HR 1.87, p=0.009). Severe dynamic LVOT obstruction (≥80 mmHg) independently predicted a higher risk of adverse clinical outcomes in patients with hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: